Company profile
Jaguar Health, Inc. logo

Jaguar Health, Inc.

Pipeline5 assets

  • CrofelemerMytesi / CFTR and CaCC channels / Botanical Drug / Gastrointestinal
    HIV-Related DiarrheaApprovedMarketedUnited StatesCancer Therapy-related Diarrhea (CTD) / Chemotherapy-induced overactive bowelPhase 3ActiveUnited StatesIrritable Bowel SyndromeIn DevelopmentActiveUnited States
  • Crofelemer Powder for Oral SolutionCFTR and CaCC channels / Botanical Drug / Gastrointestinal / Rare Disease
    Microvillus Inclusion Disease (MVID)Late StageActiveUnited StatesEuropeShort Bowel Syndrome with Intestinal Failure (SBS-IF)Late StageActiveUnited StatesEurope
  • NP-300NP-300 / Unknown / Botanical Drug / Gastrointestinal / Infectious Disease
    Cholera Diarrhea / Infectious DiarrheaIn DevelopmentActiveGlobal
  • GelclairGelclair / Unknown / Bioadherent Oral Gel / Supportive Care / Oncology
    Oral MucositisApprovedMarketedUnited States
  • Crofelemer (Animal Health)Canalevia-CA1 / CFTR and CaCC channels / Botanical Drug / Animal Health
    Chemotherapy-induced diarrhea in dogsApprovedMarketedUnited States

Latest news25 items

All news

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseases Near-term milestones for IF program buttressed by continuing groundbreaking results of study, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in

Presentation / AbstractESPGHAN e-poster presentation Sat, Jun 27, 2026

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program

Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company's crofelemer development program for rare intestinal failure diseases; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 22, 2026 /

Presentation / AbstractESPGHAN late-breaking abstract presentation Wed, Jun 24, 2026

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

Click here to register for event To access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click here Reminder: Two crofelemer presentations in pediatric intestinal failure patients with microvillus inclusion disease

Presentation / AbstractESPGHAN abstract release Wed, Jun 24, 2026

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation, is being developed as the potential first oral adjunctive therapy for Intestinal Failure (IF)

Presentation / AbstractESPGHAN late-breaking abstracts Thu, May 28, 2026

Jaguar Health Compliant with Nasdaq Bid Price Rule

JAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that

Jaguar Health Reports First Quarter 2026 Financials

Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi ® and Canalevia ® -CA1 Company continues its focus on crofelemer development efforts for rare-disease intestinal failure indications; two crofelemer

Presentation / AbstractESPGHAN abstract release Mon, Jun 1, 2026

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer as adjunctive treatment for MVID, an ultrarare pediatric disease with a lethal natural history and

Presentation / AbstractESPGHAN presentation Mon, Jun 1, 2026

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS) Jaguar has received orphan drug designations for MVID & SBS in the US and EU Jaguar has also completed enrollment of pediatric MVID

Presentation / Abstract

Jaguar Health Reports 2025 Financials

Net revenue increase of 5% in Q4 2025 vs. Q3 2025 Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi ® and Canalevia ® -CA1 - Jaguar's commercialized crofelemer drugs - with an additional $2 million due

Jaguar Health, Inc. • Endpoint Arena